MarketCapExport financials
VolitionRx Limited (VNRX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
VolitionRx Limited Income Statement 2025-2010 | VNRX
Annual Income Statement VolitionRx Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
25.2 M | 54.8 M | 58.1 M | 89.1 M | 157 M | 200 M | 185 M | 79.7 M | 92.6 M | 107 M | 66.8 M | 67.2 M | 27.1 M | 23.4 M | - | - |
Shares |
126 M | 96.1 M | 81.9 M | 57.9 M | 53.8 M | 43.4 M | 39.2 M | 31.4 M | 26.4 M | 23 M | 17.7 M | 13.4 M | 10.8 M | 9.36 M | - | 4.14 M |
Historical Prices |
0.2 | 0.57 | 0.71 | 1.54 | 2.92 | 4.08 | 3.44 | 2.95 | 3.06 | 4.42 | 3.66 | 4.11 | 2.75 | 2.5 | - | - |
Net Income |
-23.4 M | -27 M | -35.7 M | -30.6 M | -27 M | - | -16.1 M | -18 M | -14.8 M | -11.9 M | -9.53 M | -8.21 M | -3.71 M | - | -13 K | -894 K |
Revenue |
1.73 M | 1.23 M | 775 K | 306 K | 90 K | - | 17.1 K | - | - | - | - | - | - | - | - | - |
Operating Income |
-21.7 M | -27 M | -36 M | -31.8 M | -28.3 M | -21.2 M | -16 M | -17.9 M | -14.7 M | -12.4 M | -10 M | -5.95 M | -4.58 M | -4.08 M | -2.61 M | - |
Interest Expense |
-1.76 M | -233 K | 311 K | - | - | 130 K | 127 K | -111 K | 73.1 K | 20.4 K | -15.7 K | 14.8 K | - | - | - | - |
EBITDA |
-20.8 M | -25.9 M | -34.8 M | -30.8 M | -27.4 M | - | -15.4 M | -17.3 M | -14.2 M | -12.1 M | -9.77 M | -5.81 M | -4.18 M | 70 K | -13 K | 21.1 K |
Operating Expenses |
23.5 M | 28.3 M | 36.8 M | 32.1 M | 28.4 M | - | 15.9 M | 17.9 M | 15 M | 11.9 M | 9.86 M | 5.81 M | 3.36 M | 4.14 M | - | 894 K |
General and Administrative Expenses |
9.46 M | 8.49 M | 10.4 M | 10.2 M | 11.7 M | 5.47 M | 4.52 M | 5.78 M | 5.36 M | 5.43 M | 3.9 M | 1.91 M | 1.72 M | 1.3 M | - | 35.6 K |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement VolitionRx Limited
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
6.29 M | 7.93 M | 96.1 M | 110 M | 104 M | 101 M | 96.1 M | 92.4 M | 82.9 M | 82.1 M | 81.9 M | 78.3 M | 78.1 M | 63.1 M | 57.9 M | 57.5 M | 53.8 M | 53.8 M | 53.8 M | 53.2 M | 52.9 M | 50.9 M | 48.6 M | 47 M | 43.4 M | 41.2 M | 41.1 M | 39.9 M | 38.9 M | 36.2 M | 35.3 M | 32.8 M | 30 M | 27.3 M | 26.5 M | 26.5 M | 26.4 M | 26.1 M | 26.1 M | 23.5 M | 23.4 M | 19.3 M | 18.8 M | 18 M | 17.9 M | 16.5 M | 14.7 M | 13.5 M | 13.4 M | 12.2 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 8.65 M | 8.65 M | 8.65 M | 8.65 M |
Net Income |
-5.48 M | -6.66 M | - | -5.38 M | -6.28 M | -5.42 M | - | -5.87 M | -7.06 M | -8.47 M | - | -8.45 M | -9.55 M | -8.87 M | - | -7.81 M | -7.73 M | -7.72 M | - | -7.18 M | -5.57 M | -6.13 M | - | -4.34 M | -5.04 M | -5.86 M | - | -4.18 M | -4.16 M | -4.2 M | - | -4.48 M | -4.59 M | -4.65 M | - | -3.89 M | -3.46 M | -3.35 M | - | -3.48 M | -2.95 M | -2.49 M | - | -2.96 M | -1.87 M | -2.01 M | - | -5.89 M | 817 K | -2.19 M | - | -926 K | -1.05 M | -908 K | - | -2.61 M | -931 K | -802 K | - | -1.69 M | -640 K | -335 K |
Revenue |
407 K | 985 K | - | 627 K | 407 K | 246 K | - | 475 K | 396 K | 172 K | - | 165 K | 216 K | 150 K | - | 32.7 K | 39.8 K | 114 K | - | 25.5 K | 24.8 K | 25.5 K | - | 575 | 5.19 K | 544 | - | 17.1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.8 K | - | - | - | - | - | - | - | 27.6 K | 11.7 K | 15.7 K | - | - | - | - |
Operating Income |
-6.3 M | -5.35 M | - | -5.1 M | -6.3 M | -5.52 M | - | -5.87 M | -6.99 M | -8.38 M | - | -8.65 M | -9.55 M | -9.05 M | - | -7.99 M | -8.1 M | -7.68 M | - | -7.56 M | -5.9 M | -6.09 M | - | -4.5 M | -5.21 M | -5.87 M | - | -4.18 M | -4.15 M | -3.99 M | - | -4.45 M | -4.57 M | -4.63 M | - | -3.88 M | -3.44 M | -3.34 M | - | -3.48 M | -2.98 M | -2.49 M | - | -2.97 M | -2.02 M | -2.35 M | - | -1.76 M | -1.05 M | -1.24 M | - | -926 K | -1.05 M | -908 K | - | -873 K | -931 K | -802 K | - | - | - | - |
Interest Expense |
-16.3 K | -1.35 M | - | -309 K | -16.3 K | 45.1 K | - | 129 | -69.8 K | - | - | - | - | - | - | - | - | 41 K | - | 38.8 K | 39.7 K | 42.2 K | - | 34.7 K | 22.6 K | 33.8 K | - | 32.3 K | 33.1 K | -30.1 K | - | -29.1 K | 26.6 K | 23 K | - | 17.6 K | 20.4 K | 12.2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-6.3 M | -5.14 M | - | - | - | -5.27 M | - | - | - | -8.12 M | - | - | - | -8.77 M | - | -7.31 M | -7.65 M | -7.45 M | - | -6.85 M | -5.43 M | -5.86 M | - | -3.98 M | -4.85 M | -5.69 M | - | -3.67 M | -3.81 M | -3.82 M | - | -3.97 M | -4.25 M | -4.47 M | - | -3.5 M | -3.22 M | -3.25 M | - | -3.25 M | -2.82 M | -2.42 M | - | -2.8 M | -1.93 M | -2.31 M | - | -1.66 M | -987 K | -1.21 M | - | -817 K | -975 K | -871 K | - | -769 K | -862 K | -769 K | - | 77.6 K | 47.6 K | 23.9 K |
Operating Expenses |
6.7 M | 6.33 M | - | 5.73 M | 6.7 M | 5.77 M | - | 6.34 M | 7.39 M | 8.56 M | - | 8.82 M | 9.77 M | 9.19 M | - | 8.03 M | 8.14 M | 7.79 M | - | 7.59 M | 5.93 M | 6.11 M | - | 4.5 M | 5.22 M | 5.87 M | - | 4.19 M | 4.15 M | 3.99 M | - | 4.45 M | 4.57 M | 4.63 M | - | 3.88 M | 3.44 M | 3.34 M | - | 3.48 M | 2.98 M | 2.49 M | - | 2.97 M | 2.02 M | 2.35 M | - | 1.78 M | 1.05 M | 1.24 M | - | 926 K | 1.05 M | 908 K | - | 900 K | 943 K | 817 K | - | - | 640 K | 335 K |
General and Administrative Expenses |
2.94 M | 2.63 M | - | 2.48 M | 2.94 M | 2.24 M | - | 1.82 M | 2.28 M | 2.25 M | - | 2.6 M | 2.64 M | 2.58 M | - | 2.76 M | 3.09 M | 2.6 M | - | 3.14 M | 2.43 M | 1.81 M | - | 1.08 M | 1.51 M | 1.7 M | - | 1.35 M | 1.44 M | 1.23 M | - | 1.45 M | 1.64 M | 1.84 M | - | 1.56 M | 1.43 M | 1.4 M | - | 164 K | 166 K | 228 K | - | 141 K | 122 K | 248 K | - | 129 K | 51.8 K | 68.9 K | - | 68 K | 123 K | 51.6 K | - | 48.2 K | 149 K | 38 K | - | 54.7 K | 45.1 K | 49.9 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company VolitionRx Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K |  USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 257.93 | 1.18 % | $ 28.6 B | USA |
 |
Danaher Corporation
DHR
|
$ 230.45 | 1.76 % | $ 164 B | USA |
 |
IDEXX Laboratories
IDXX
|
$ 676.3 | 0.83 % | $ 54.4 B | USA |
 |
Illumina
ILMN
|
$ 213.05 | 2.43 % | $ 33 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 100.61 | -0.09 % | $ 6.79 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
$ 653.24 | 2.88 % | $ 18.8 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 722.36 | 2.64 % | $ 35.5 B |  Schweiz |
 |
Natera
NTRA
|
$ 319.38 | -12.2 % | $ 43.7 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 338.13 | 8.07 % | $ 16.8 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 30.33 | -0.57 % | $ 28.8 B |  Niderland |
 |
QIAGEN N.V.
QGEN
|
$ 50.36 | -0.98 % | $ 10.9 B | Niderland |
 |
RadNet
RDNT
|
$ 75.83 | -2.79 % | $ 5.7 B | USA |
 |
Senseonics Holdings
SENS
|
$ 8.58 | 7.38 % | $ 358 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
$ 2.17 | -10.91 % | $ 143 M | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 694.85 | 2.62 % | $ 262 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Trinity Biotech plc
TRIB
|
$ 6.07 | 2.97 % | $ 2.18 B |  Irlanda |
 |
Brainsway Ltd.
BWAY
|
$ 11.12 | 4.81 % | $ 378 M |  Israel |
 |
Waters Corporation
WAT
|
$ 458.04 | 1.06 % | $ 27.3 B | USA |
 |
Exagen
XGN
|
$ 5.79 | -23.82 % | $ 125 M | USA |
 |
Guardant Health
GH
|
$ 151.28 | -1.4 % | $ 19 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 366.98 | 1.02 % | $ 30.5 B | USA |
 |
IQVIA Holdings
IQV
|
$ 271.72 | 2.59 % | $ 46.7 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
Celcuity
CELC
|
$ 66.73 | 3.9 % | $ 3.12 B | USA |
 |
DexCom
DXCM
|
$ 79.42 | -5.97 % | $ 31 B | USA |
 |
Agilent Technologies
A
|
$ 175.14 | 1.97 % | $ 49.7 B | USA |
 |
Castle Biosciences
CSTL
|
$ 32.49 | -4.99 % | $ 942 M | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.16 | 4.29 % | $ 103 K | USA |
|
Biodesix
BDSX
|
$ 8.51 | -57.13 % | $ 64.3 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.15 | 4.54 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
$ 10.61 | -0.66 % | $ 707 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 23.68 | 26.9 % | $ 729 M | USA |
 |
CareDx, Inc
CDNA
|
$ 78.47 | 2.8 % | $ 4.18 B | USA |